Huang who requested that the compound be tested for anti-2
inflammatory activity in the Monsanto COX-1/COX-2 inhibition
assay. According to Koboldt, she received material identified
as SC-60246,
SC-60247, SC-60248, SC 60668, and SC-60668 from Dr.
Chamberlain for testing in the assay in February and March of
1994 (Exh. 2029 at ¶¶4-6).
43. The Monsanto assay is said to be an assay that
tests a compound for its ability to inhibit COX-2 selectively
over COX-1 (Paper 46 at 13).
44. The Monsanto assay is an in vitro assay.
45. According to Koboldt, the results for each
tested compound, which were recorded in her notebook (Exh.
2038), showed the compound to have selectivity for COX-2
inhibition (Exh. 2029 at ¶9). In particular, Koboldt
testified that SC-58394 was tested on 20, 23, and 28 September
1993. Based on results she obtained, Koboldt testified that
she expected each tested compound, including SC-58394, to have
pharmacologically useful anti-inflammatory properties (Exh.
2029 at ¶¶9-14).
2 We understand "Henry Huang" to be Dr. Horng-Chi Huang. If this is
not the case, Huang should inform the Board upon receipt of this decision.
17
Page: Previous 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Next
Last modified: November 3, 2007